monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

ESMO 2025

Breast Cancer

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

SABCS 2024

Breast Cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

ESMO 2025

Breast Cancer

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

SABCS 2024

Breast Cancer

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

SPECIAL REPORT

Breast Cancer

Abémaciclib dans le cancer du sein HR-positif/HER2-négatif, avec atteinte ganglionnaire chez les femmes au stade précoce

SABCS 2024

Breast Cancer

Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

ESMO 2025

Breast Cancer

NATALEE: Ribociclib plus adjuvant endocrine therapy sustains iDFS benefit two years post-treatment in patients with HR+/HER2− breast cancer

Breast Cancer

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial

Ann Oncol

Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D

doi: 10.1016/j.annonc.2024.10.015

SPECIAL REPORT

Breast Cancer

Related content

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

Abémaciclib dans le cancer du sein HR-positif/HER2-négatif, avec atteinte ganglionnaire chez les femmes au stade précoce

Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

NATALEE: Ribociclib plus adjuvant endocrine therapy sustains iDFS benefit two years post-treatment in patients with HR+/HER2− breast cancer

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study